Chemoprevention of breast cancer

References

• Parkin DM, Bray F, Ferlay J et al. Global cancer statistics 2002. CA Cancer J. Clin.55(2), 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer101, 3–27 (2004).
   PubMed Web of Science ®Google Scholar
• Weir HK, Thun MJ, Hankey BF et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl Cancer Inst.95, 1276–1299 (2003).
   PubMed Web of Science ®Google Scholar
• Harlan LC, Abrams J, Warren JL et al. Adjuvant therapy for breast cancer: practice patterns of community physicians. J. Clin. Oncol.20, 1809–1817 (2002).
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Hawk ET, Crowell JA et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology10, 1471–1488 (1996).
   PubMedGoogle Scholar
• Beatson GT. On the treatment of inoperable cases of carcinoma of the mama: suggestion for a new method of treatment with illustrative cases. Lancet2, 104–107 (1896).
   Google Scholar
• Feinleib M. Breast cancer and artificial menopause: a cohort study. J. Natl Cancer Inst.41, 315–329 (1968).
   PubMed Web of Science ®Google Scholar
• Lupulescu AP. Hormones, vitamins and growth factors in cancer treatment and prevention. Cancer78(11), 2264–2280 (1996).
   PubMed Web of Science ®Google Scholar
• Dickson R, Lippman ME. Growth factors in breast cancer. Endocr. Rev.16, 559 (1995)
   PubMed Web of Science ®Google Scholar
• Janis K, Hoeltke J, Nazareth M et al. Estrogen decreases expression of chemokine receptors, and suppresses chemokine bioactivity in murine monocytes. Am. J. Reprod. Immunol.51(1), 22–31 (2004).
   Google Scholar
• Jiang X, Ellison SJ, Alarid ET, Shapiro DJ. Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene26(28), 4106–4114 (2007).
   PubMedGoogle Scholar
• Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas35, 3–9 (2000).
   PubMed Web of Science ®Google Scholar
• Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther.25, 127–205 (1984).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst.90(18), 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Brown A et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol.4, 459–471 (1986).
   PubMed Web of Science ®Google Scholar
• Fisher B, Constantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N. Engl. J. Med.320, 479–484 (1989).
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst.81, 1879–1886 (1989).
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst.97, 1652–1662 (2005).
   PubMed Web of Science ®Google Scholar
• Powles T, Eeles R, Ashley SE, Easton D, Chang J, Dowsett L. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet352, 98–101 (1998).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet352, 93–97 (1998).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet360, 817–824 (2002).
   PubMed Web of Science ®Google Scholar
• Vogel VG. Raloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal women. Women Health3, 139–153 (2007).
   Google Scholar
• Jordan VC, Morrow M. Tamoxifen, raloxifen and the prevention of breast cancer. Endocr. Rev.20, 253–278 (1999).
   PubMed Web of Science ®Google Scholar
• Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J.10(8), 905–912 (1996).
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA281, 2189–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E et al. Continuing outcomes relevant to evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst.96, 1751–1761 (2004).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med.355, 125–137 (2006).
   PubMed Web of Science ®Google Scholar
• Pines A, Levo Y. Why is the RUTH trial so important? Maturitas56(2), 111–112 (2007).
   Google Scholar
• Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet361, 296–300 (2003).
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet351, 1451–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study Of Tamoxifen And Raloxifene (STAR) P-2 trial. JAMA295, 2727–2741 (2006).
   PubMed Web of Science ®Google Scholar
• Lonning PE. Pharmacology of new aromatase inhibitors. Breast5, 202–208 (1996).
   Web of Science ®Google Scholar
• Evans CT, Ledesma DB, Schulz TZ et al. Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. Proc. Natl Acad. Sci. USA83, 6387–6391 (1986).
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Anker G et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin. Cancer Res.4, 2089–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist11(6), 553–562 (2006).
   PubMed Web of Science ®Google Scholar
• Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT)for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – a randomized Phase III trial of the EORTC Breast Group. Proc. Am. Soc. Clin. Oncol.23,6 (2004).
   Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21, 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J. Clin. Oncol.18, 3758–3767 (2000).
   PubMed Web of Science ®Google Scholar
• Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer98, 1802–1810 (2003).
   PubMed Web of Science ®Google Scholar
• Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum. Reprod.9(7), 1364–1379 (1994).
   PubMed Web of Science ®Google Scholar
• Schally AV, Arimura A, Kastin AJ et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science173, 1036–1038 (1971).
   PubMed Web of Science ®Google Scholar
• Sharoni Y, Bosin E, Miinster A, Levy J, Schally AV. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc. Natl Acad. Sci. USA86, 1648–1651 (1989).
   PubMedGoogle Scholar
• Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception47, 427–444 (1993).
   PubMed Web of Science ®Google Scholar
• Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell. Mol. Life Sci.61, 1475–1484 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JS, Newman RA, Lippman SM et al. Phase I evaluation of all-transretinoic acid in adults with solid tumors. J. Clin. Oncol.11, 959–966 (1993).
   PubMed Web of Science ®Google Scholar
• Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl Cancer Inst.91, 1847–1856 (1999).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Mariani L, Decensi A et al. Fifteen-year results of a randomized Phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol.17(7), 1065–1071 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang S, Hunter DJ, Forman MF et al. Dietary carotenoids and vitamins A, C and E and risk of breast cancer. J. Natl Cancer Inst.91(6), 547–556 (1999).
   PubMed Web of Science ®Google Scholar
• Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst.90, 1529–1536 (1998).
   PubMed Web of Science ®Google Scholar
• Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 gene expression in human breast cancer. Int. J. Oncol.10, 503–507 (1997).
   PubMed Web of Science ®Google Scholar
• Hawk ET, Viner JL, Asad Umar A et al. Development of COX inhibitors in cancer prevention and therapy. Am. J. Cancer26, S48–S57 (2003).
   Google Scholar
• Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA294(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall SF, Bernstein L, Anton-Culver H et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J. Natl Cancer Inst.97(11), 805–812 (2005).
   PubMed Web of Science ®Google Scholar
• Adlercreutz CH, Goldin BR, Gorbach SL et al. Soybean phytoestrogen intake and cancer risk. J. Nutr.125, S757–S770 (1995).
   PubMed Web of Science ®Google Scholar
• Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene. Biochem. Biophys. Res. Commun.179, 661–667 (1991).
   PubMed Web of Science ®Google Scholar
• Sarkar FH, Li Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev.21(3–4), 265–280 (2002).
   PubMed Web of Science ®Google Scholar
• Barnes S. The chemopreventive properties of soy isoflavonoids in animal models of breast cancer. Breast Cancer Res. Treat.46, 169–179 (1997).
   PubMed Web of Science ®Google Scholar
• Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res. Treat.77(2), 171–183 (2003).
   PubMed Web of Science ®Google Scholar
• Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res.61, 5045–5050 (2001).
   PubMed Web of Science ®Google Scholar
• Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia16(4), 508–519 (2002).
   PubMed Web of Science ®Google Scholar
• Friis S, Poulsen AH, Johnsen SP et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer114, 643–647 (2005).
   PubMed Web of Science ®Google Scholar
• Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin. Cancer Res.9, 10–19 (2003).
   PubMed Web of Science ®Google Scholar
• Kochhar R, Khurana V, Bejjanki H et al. Statins reduce breast cancer risk: a case control study in U.S. female veterans. J. Clin. Oncol.23(Suppl. 7) (2005). (Abstract 514).
   Google Scholar
• Bonovas S, Filioussi K, Tsavaris N et al. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J. Clin. Oncol.23, 8606–8612 (2005).
   PubMed Web of Science ®Google Scholar
• Prowell TM, Stearns V, Trock B. Lipophilic statins merit additional study for breast cancer chemoprevention. J. Clin. Oncol.24(13), 2128–2129 (2006).
   PubMedGoogle Scholar
• Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol. Biomarkers Prev.10, 467–473 (2001).
   PubMed Web of Science ®Google Scholar
• Kauff ND, Satagopan JM, Robson ME et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med.346(21), 1609–1615 (2002).
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, van Geel B, van Putten WLJ et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2mutation. N. Engl. J. Med.345, 159–164 (2001).
   PubMed Web of Science ®Google Scholar
• King M-C, Wieand S, Hale K et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) breast cancer prevention trial. JAMA286, 2251–2256 (2001).
   PubMed Web of Science ®Google Scholar